Ladies and gentlemen, thank you for standing by, and welcome to the Elanco Animal Health Inc. Q2 2021 Earnings Call. At this time, all participants are in a listen only mode. After the speaker presentation, there will be a question and answer I would now like to hand the conference over to your speaker today, Tiffany Kanaga. Thank you.
You may begin.
Good morning. Thank Thank you for joining us for Elanco Animal Health's 2nd quarter 2021 earnings call. I'm Tiffany Kanaga, Head of Investor Relations. Joining me on today's call are Jeff Simmons, our President and Chief Executive Officer Todd Young, our Chief Financial Officer and Katie Grissom from Investor Relations. As always, during this conference call, we anticipate making projections and forward looking statements based on our current expectations.
Our actual results could differ materially due to a number of factors, including those listed on slide 2 and those outlined in our latest Forms 10 ks and 10 Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. You can find our press release and the slides referenced on this call in the Investors section of elanco.com. The slides and the press release also contains further information about the non GAAP financial measures that we will discuss today during this call.
After our prepared remarks, we will be happy to take your questions. I will now turn the call over to Jeff to provide
Thanks, Tiffany. Good morning, everyone. As I reflect on our progress in the nearly 8 months since our Investor Day, We see evidence that our transformation is creating sustainable long term value for our customers, our shareholders and our global Elanco team. Our results demonstrate we are executing against the strategy we laid out in December. 2nd quarter revenue, EBITDA and EPS on Slide 4 were all above our expectations, continuing to build on the strong momentum our business has Past the midpoint of our guidance range by nearly $40,000,000 without performance in both sides of our now relatively balanced business between Pet Health and Farm Animal.
Our adjusted EPS of 0.28 dollars was 0 point 0 $4 above the midpoint of guidance, including an approximately $0.03 headwind from discrete items in the quarter that pushed our tax rate to nearly 30%, more than offset by approximately $0.07 of operating improvement. Adjusted EBITDA of $291,000,000 was $29,000,000 above the midpoint, demonstrating good flow through And showing significant headway toward our long term margin targets. Today, we are raising our 2021 Full year revenue guidance for the 3rd time by $15,000,000 at the midpoint to 4 point $6,800,000,000 to $4,730,000,000 The business is delivering beyond our long term growth algorithm, providing total revenue up 5% to 7%. This includes approximately 4% to 5% for our underlying business, With a reduced innovation range entirely due to external challenges for ZolaShield, which I'll discuss later, that is more than offset by portfolio gains and a good industry backdrop. While we exit the 2nd quarter with strong momentum, we're taking approach to the rest of the year, factoring in many moving pieces, including seasonality, moderation in pandemic driven pet health Tailwinds in the vet clinic and ongoing competitive dynamics.
During the Q2, we made 2 strategic moves with Some near term implications and important medium and long term benefits. First, we announced the bolt on acquisition of KindredBio, which can contribute 3 potential blockbusters alongside our own dermatology assets and more quickly build a presence in this essential part of the industry. The transaction also provides shots on goal in other therapeutic fields, including securing full ownership of the canine parvovirus therapy. We've completed antitrust review and expect the transaction to close this month. 2nd, we announced the exit of the 3 manufacturing sites.
In further streamlining our footprint, we're accelerating our gross margin efforts, Reducing annual CapEx and improving working capital. Todd will provide details on how these Two decisions impact our revenue, EBITDA and EPS in 2021. Both strategic moves are examples Moving now to overall pet health for the quarter on Slide 5, the global business drove approximately 2 thirds of the upside versus the midpoint of the guidance, reaching $685,000,000 in revenue for the quarter, with continued good execution in a competitive but favorable pet industry. As you know, pet spending Has many structural tailwinds, which were amplified during the pandemic. Industry research shows that the number of U.
S. Pet owning households surged by nearly 6 percent in 2020 versus the slightly positive pre COVID run rate. This trend is not isolated to America with 3,200,000 UK Households having acquired a pet since the start of the pandemic and a 2020 survey by the Japan Pet Food Association showing a 15% increase in dog and cat ownership. This increased pet ownership also drove greater vet Our pet health vaccine business was a standout in the quarter in this beneficial vet clinic backdrop. Vaccines were a key driver of Elanco's 2% improvement in price, reinforcing that our channel strategy is working and creating real demand.
Our aggregate channel inventory levels at distribution remain consistent with prior quarters in the U. S. And across the global business. Turning to parasiticide, 2nd quarter global Seresto revenue was $129,000,000 down 1% year over year and Global Aid Family revenue was $148,000,000 down 3%. Both faced Similar dynamics with a tough comparison against last year's retailer driven stock in and Seresto also lapped a meaningful increase and points of distribution at certain major retailers.
Additionally, cooler and wetter weather in May across many parts of the U. S. Impacted seasonal traffic In the broader OTC channel as seen in the Nielsen data, Seresto and A family trends rebounded in June alongside the industry with more favorable weather. Moreover, both achieved gains outside the U. S.
In the quarter, Leading our overall performance in international pet health. We remain on track toward full year expectations for Seresto. The brand's resilient performance demonstrates high levels of confidence among consumers and veterinarians. Let me add that the EPA's 60 day public comment period, which opened July 13th following an NGO petition, is a standard and expected practice. We have full confidence in Seresto's strong safety profile, which is supported by registrations from more than 80 regulatory bodies around the world And our robust pharmacovigilance process.
We continue to see a long runway to grow this trusted brand. Browning out parasiticides, the Credelio franchise drove healthy growth across its combined platform of U. S. Vet clinics, Retail and international, along with the launches of both Credelio Plus and Credelio Cat. In the U.
S. Market, Credelio maintained robust double digit EDI growth in the 2nd quarter, representing outbound sales into the vet performing well in light of industry innovation, which is driving greater than anticipated share erosion from our older Defend brand, Trifexis. We will continue to maximize profitability with target investments across our portfolio and grow revenue through new innovation as we compete for greater share of the expanding growing global parasiticide market. Our combined international portfolio is highly competitive And both parasiticides and therapeutics bolstered by our outperformance from new innovation like Credelio Plus. Finally, in therapeutics, Galliprant continued its global expansion and also posted double digit EDI growth in the 2nd quarter with year to date share gains in the branded U.
S. Inset market according to the kinetic data. While we exceeded 2nd quarter guidance and exit the quarter with good momentum, we head into the remainder of the year with a number of variables to consider. We believe pet health is recalibrating back towards normalcy against tougher comparisons and with a natural moderation of tailwinds from the puppy We're watching vet clinic trends in light of the limited practice capacity and labor constraints. We're monitoring pet ownership trends as the economy opens especially in the US, and ectoparasiticides.
In balance, our pet health strategy is tracking to overall expectations. Innovation is performing ahead of plan, driving growth alongside focused brand contributions. We have Omnichannel leadership and digital initiatives to generate long term growth with expansion in new regions like China, all supporting our full year outlook And more consistent and competitive levels of pet health growth over time. Turning now to our farm animal business. In the Q2, we saw demand driven improvement in our U.
S. Cattle and swine businesses, with protein benefiting from a return to food service. The first half of twenty twenty one also benefited from higher numbers of cattle on feed. Elevated and volatile feed Costs continue to pressure producer economics, likely extending through the back half of the year. However, They enhanced the value proposition for our efficiency products like SkySys, Optiflex and Rumensin, which all outperformed our forecast in the quarter.
In China swine, we experienced impacts from the reemergence of African swine fever. Hog prices ended the quarter, down about 65% since the start of the year, Severely pressuring profitability for Chinese producers. The sow herd reduction is likely to also impact the Q3. But overall, we still expect our China business to deliver at least a percentage point of growth to total Elanco revenue in 2021. Finally, international poultry and aqua remain negatively affected by unfavorable macroeconomic conditions iNav is also beginning to benefit from our recently published Phase 4 study demonstrating superior ROI versus alternatives.
Q2 also saw a very robust lift from the timing of Aqua orders shifting into the period from the 3rd quarter. While we do remain cautious around these businesses, we anticipate overall improvement ahead against a soft COVID driven comparison. As you will see on Slide 6, our 2nd quarter outperformance is driven by disciplined execution against our strengthened and expanded IPP strategy. I'd like to share more on our innovation progress on Slide 7 with Around the 8 launches planned this year. Pet health innovation is running above expectations, and I'm pleased with the global team's commercial execution around each of these three launches.
Credelio Plus is exceeding plan in Japan and Europe And is on track to launch in Australia in Q3 in time for the local parasiticide season. While differing thresholds around heartworm production Prevent us from bringing this product to the U. S, Credelio Plus is proving to be very competitive in the $1,500,000,000 international market. Meanwhile, Credelio Cat and Allura are growing our feline portfolio. In farm animal, Entrexa is faring well in a competitive and unprecedented market dynamic.
It remains early days for Experior, We're making important strides towards achieving Packer ecosystem integration with continued potential for blockbuster status. Exterior's value proposition is being validated in the field and packer acceptance is growing, now reaching 7 packers versus 1 at the end of Q1. The first Exterior customers have now reordered product and expanded use. Finally, ZoaShield, which we source externally to build our portfolio in the raised without antibiotics space. As a result, we're taking a prudent approach to total pipeline forecast in 2021, reducing our innovation revenue outlook by $15,000,000 to $65,000,000 to $85,000,000 However, we remain confident in the value contributions of ZolaShield to our poultry portfolio.
It's important to understand that this year's reduction does not impact 2025 total innovation potential of $600,000,000 to $700,000,000 which we raised in mid June with the announcement of the KindredBio acquisition. Before I turn the call over, let me say a few words on the regulatory item. On July 1, Elanco Received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-twenty 20. We've cooperated in providing documents and information to the SEC and will continue to do so. We believe strongly that our actions were appropriate.
Finally, I'd like to just stop and thank our entire global team for continued diligent execution and Focus during these unprecedented times. From our South Africa colleagues determining how to reach customers amid riots To those in Vietnam sleeping in our plant to ensure supply amid another COVID lockdown, their commitment to our purpose is unwavering and inspiring. With that, I'll hand it over to Todd to provide more color on our results and our outlook.
Thanks, Jeff. Slide 8 summarizes our financial performance highlights, including our reported net income and earnings per share. On Slide 31 to 40 in the appendix, you can find a summary of the adjustments made to the reported results to arrive at our adjusted presentation. I'll focus my comments on our 2nd quarter adjusted measures in order to provide insights on the underlying trends in our business, so please refer to today's earnings press release for a detailed description of the year over year changes in our reported results. Looking at the adjusted measures on Slide 9, You'll see that total Elanco revenue increased 118% in the quarter on a reported basis with 5 points of benefit from foreign exchange for legacy Elanco.
Our 2nd quarter revenue on a pro form a combined company basis would have represented growth of approximately 10%, assuming the Bayer acquisition had happened at started the year and adjusting for the impact of strategic distribution changes. On Slide 10, there is a visual representation of our revenue outperformance versus the guidance range we provided in May. The key drivers, an order of magnitude, were commercial execution in our international pet health business, Continued improvement in U. S. Cattle and swine, currency tailwinds and order phasing in Aqua.
Adjusted gross margin as a percent of revenue was 57%, an increase of 7.50 basis points compared to the Q2 of last year. The year over year improvement reflects the Bayer acquisition that dramatically increased our exposure to the rapidly growing pet Also, that this higher margin portfolio is first half weighted due to the Northern Hemisphere's flea and tick season. Additionally, we saw the benefit of positive price and volume on Elanco's legacy portfolio and continued productivity gains. The sequential deceleration of 2 20 basis points versus the Q1 includes impact from a temporary plant shutdown due to a weather induced power outage, Logistics costs and the shift of some expenses into the 2nd quarter with the lazy Elanco ERP cutover as discussed last quarter. Total operating expense increased 116% in the 2nd quarter, driven by the addition of the Bayer Animal Health At $475,000,000 the amount was $42,000,000 above the Q1 and includes the previously identified Approximately $30,000,000 shift of investments into the 2nd quarter.
The delayed expenses included more opportunistic Our top line execution, expense leverage and discipline and synergy execution. The sequential step down of $47,000,000 The Q1 is attributable to the sequential gross margin and shifting investment impacts I just described. Our adjusted EBITDA was $291,000,000 and our adjusted EBITDA margin for the quarter was 22.8%. At the bottom line, Q2 adjusted net income increased 2 74 percent to $135,000,000 Reflecting our effective tax rate of 29.6%. 2 discrete items primarily drove our rate above our prior Full year forecast of 21% to 22%.
First, tax rate changes in several jurisdictions required the remeasurement of our deferred tax assets liabilities with the net impact adding nearly $5,000,000 to our Q2 tax expense. The largest impact was in the UK With a tax rate increase from 19% to 25%, resulting in $3,000,000 in additional tax expense. This impact will not repeat. 2nd, we finalized a number of international tax return to provision and transfer price adjustments that increased our expense by nearly $4,000,000 For the back half of the year, we anticipate an effective tax rate in the 22% to 23% range. Now, let's discuss our revenue performance more closely.
On Slide 11, you will see a breakdown of the contribution from legacy Elanco Legacy bear portfolios by category. Legacy bear products contributed $529,000,000 in the quarter. Pet health drove $685,000,000 of revenue or 54 percent of total Elanco. Cattle contributed $231,000,000 or 18 percent of total Elanco revenue in the quarter, poultry added $179,000,000 representing 14%, Swine, dollars 113,000,000 or 9 percent and aqua, dollars 44,000,000 or 3%. On Slide 12, you can see the effect of price, rate and volume on our revenue performance.
The benefit of the Bayer acquisition is reflected in volume. We will continue to report the addition of the Bayer business in volume to the Q3 of 2021 when we lap the transaction close. For the legacy Elanco business, price was up 2% for the quarter led by pet health vaccines and demonstrated the value of our innovation, The discipline we are applying despite competitive pressures and enhanced commercial execution, all continued evidence that our channel strategy is working. Farm animal price was flat in the quarter, reflecting competitive dynamics in U. S.
Cattle and swine. We continue to target A 2% increase for the total business in 2021 with revenue management in focus as we are observing some inflationary pressures in areas such as transportation costs. Slide 13 provides a breakdown of our overall performance between the U. S. And our international operations.
We have further outlined our geographic performance by pet health and farm animal as well as contract manufacturing, all of which benefited from the addition of Bayer. We expect to file our 10 Q shortly, but moving to Slide 14, let me offer a few words on working capital, Operating cash flow and debt pay down. In the U. S, consistent with the prior four quarters, we held all distributors at 60 day payment terms. In the Q2, Dave sales outstanding stood at 75 days, up from 69 in the Q1 as our average accounts receivable throughout Q2 was higher as a result of Q1 revenue being significantly higher than Q4 revenue.
We ended the 2nd quarter with $580,000,000 in cash We have secured a commitment for additional prepayable floating rate bank debt of $500,000,000 to refinance our $500,000,000 of senior notes that come due on August 27. We will use cash from our balance sheet And draw on our revolving credit facility to fund the KindredBio acquisition. Consequently, we expect net leverage of 5.5 times at the end of 2021, in line with our original projection from December 2020. Before I discuss our guidance, I'd like to remind everyone of the 2021 financial impacts from streamlining our manufacturing footprint announced June 9. We closed the sale of the Shawnee, Kansas site on August 1, removing $10,000,000 to $20,000,000 of associated contract manufacturing revenue in the last 5 months of this year.
This impact was reflected in the guidance we confirmed when we announced the KindredBio acquisition on June 16th. We do not expect an impact to adjusted EPS from the sale, but we do anticipate a $5,000,000 to $10,000,000 EBITDA headwind in 2021, including an effect on depreciation. Please refer to our press release this morning for the GAAP impact to our 2nd quarter results from this divestment. With respect to the KindredBio acquisition, we expect slight dilution to both reported and adjusted EPS for the full year 2021 An approximately $10,000,000 impact to net loss and approximately $10,000,000 impact to EBITDA as we continue execute against KindredBio's R and D programs. Now we'll transition to our full year and Q3 2021 outlook starting on Slide 16.
We are raising our full year 2021 guidance for total revenue and updating EBITDA and EPS for a number of factors, including our 2nd quarter outperformance. We now anticipate 2021 revenue of $4,680,000,000 to $4,730,000,000 including the loss of $10,000,000 to $20,000,000 of contract manufacturing revenue from the Shawnee facility exit. To walk from our last update in June on Slide 17, our increased outlook flows through the approximately $40,000,000 outperformance in the 2nd quarter, partly offset by a reduced outlook this year for ZoaShield and the impact of Aqua order phasing. Slide 18 offers a refreshed view of the bridge from our 2020 combined company revenue to our 2021 guidance. In comparison to our May update, we now expect innovation to contribute $65,000,000 to $85,000,000 in new revenue.
This reduced range is offset by growth in our base portfolio. As a result, we anticipate approximately 4% to 5% underlying growth for the year and 5% to 7% total growth. Moving to Slide 19, we expect adjusted EBITDA of 1.035 to $1,075,000,000 based on adjusted gross margin of 56.75% to 57% and OpEx of $1,780,000,000 to $1,800,000,000 Our gross margin rate is being negatively impacted by increased logistics expense Our depreciation assumption, including the impact of our manufacturing exits and expenses associated with KindredBio, mostly offset by our Q2 outperformance of nearly $30,000,000 Our full year spend continues to incorporate strategic investments in commercial growth opportunities. Slide 20 provides the moving pieces informing our updated adjusted and reported EPS guidance range. Our adjusted EPS outlook, which is $0.03 lower than the range discussed in May, factors in $0.02 of dilution from KindredBio, dollars 0.02 of the impact From the Zohr Shield and Aqua phasing, dollars 0.03 from logistics and inflation and $0.03 from the discrete tax items affecting Q2.
We are flowing through the $0.07 of operational execution and outperformance from Q2 to arrive at our revised 2021 guidance of $0.97 to $1.03 Our outlook demonstrates the underlying fundamentals of our business remain strong into the balance of the year. The reported EPS bridge likewise closed through the 2nd quarter outperformance and the aforementioned items as well as the $0.46 write down finalized from the manufacturing streamlining announcement. The impact Reported earnings from integration and stand up are sequentially decreasing in magnitude from approximately $80,000,000 in Q1 of 2021 to approximately $20,000,000 this quarter. Moving to Slide 21, We are providing guidance for the Q3 of 2021. We expect revenue of $1,075,000,000 to $1,100,000,000 Adjusted EBITDA of $195,000,000 to $220,000,000 and adjusted EPS of $0.15 to $0.19 Our outlook, which is a sequential step down from the first half of the year, reflects the seasonality of our combined company and the resulting quarterly cadence as detailed in our call in May.
Remember, just over 70% of Seresto revenue and just under 60% of the Vantage family revenue occurs in the first half of the year on average. Given the relative scale of these products and their margin contribution, The revenue timing translates to an outsized first half contribution to EPS as well. Now I'll hand it back to Jeff for closing comments.
Thanks, Todd. To summarize, Elanco is moving through 2021 with strong results extending our track record of execution Since acquiring Bayer Animal Health and driving long term strategic actions with the expected acquisition of KindredBio, further streamlining our manufacturing footprint and delivering on our vision of food and companionship in reaching life. We head into the back Half of the year with confidence in our ability to drive sustainable double digit adjusted EBITDA and adjusted EPS growth, Anchored by steady growth on the top line. Our fundamentals are healthy with our core R and D pipeline tracking to plan and robust portfolio growth resulting in above algorithm revenue velocity in 2021. Our productivity agenda continues to deliver with rapid action towards synergy capture.
Finally, I'd like to express a heartfelt thank you to Katie Grissom as She transitions to a new role in global marketing finance. Katie has been an instrumental part of the IR team during our journey since the IPO, And I look forward to the impact of her contributions in our commercial organization. With that, I'll turn it over to Tiffany to moderate the Q and A.
Thank you, Doug. We'd like to take questions from as many callers as possible. So we ask that you limit yourself to one question and one follow-up. April, please provide the instructions for the Q and A session and then we'll take the first caller.
And your first question is from Michael Ryskin with Bank of America.
Thanks. Hi, thanks for taking the question this morning. I want to start on sort of the guide methodology and the rash Now from early in the year and I think Slide 16 in your deck summarizes it really well. You raised the guide a number of This year, most recently in May. And now we're in a situation where you're lowering it on adjusted EBITDA, adjusted EPS despite the solid second quarter.
And obviously, that's a little bit disappointing. So I'm just wondering if given all the moving pieces in the Bayard or the moving pieces in the underlying market, It'd be more prudent to take a more conservative approach, leave more wiggle room for things like the Zillow Shield update
and some
of the The logistics costs and inflationary pressures.
Mike, appreciate the question. We've been trying to give the, Yes. I guess most consistent and best information we have at the time when providing guidance. When we did the Kindred deal as well as The streamlining of our manufacturing, those did have impacts on EPS as well as EBITDA. We've provided the bridges in the slides To try to clearly show that, those are the key items.
We've had the over performance from Q2 that we factored in, plus This tax rate impact in Q2 that despite the tax rate and cost us about $0.03 of EPS As a result of the law changes in the UK as well as some return to provision adjustments. So overall, we've been very pleased with the underlying Growth in our business, as noted, the portfolio contribution from our products is growing faster now than we had previously communicated, which We view as a very big positive. The one off with the ZoaShield on supply, again, that's something that we thought would play out differently at the start of the year. We're still confident in our Raised without antibiotic portfolio going forward. So overall, we're trying to be as clear on the moving pieces.
And again, second half is very much in line or slightly better on our total Elanco portfolio than we expected back in May, Offset by some of the inflationary jumps on the logistics side the team is managing.
We'll take the next caller.
Your next question is from Umer Raffat with Evercore ISI.
Hi, guys. Thanks so much for taking my question. Jeff, in your prepared remarks, you mentioned, an SEC is looking into the inventory practices. Could you expand on that a bit more? Are they what specifically are they alleging?
And do you expect this to be a multiyear process before any sort of resolution comes? At least that's what's been the observation with Similar investigations that you see done on other companies in the past.
Yes. Thank you, Umer, for the Let me just reiterate. Yes, on July 1 this year, our company received a subpoena from the U. S. SEC.
It was relating to our channel inventory and sales practices prior to the mid-twenty 20 period And the company has cooperated in providing the documents and information to the SEC at this stage and will continue to do so. And as I stated, management, starting with myself, believes strongly that our actions were appropriate. Now, Umer, maybe to put this in Proper context that I think is important in what you're asking for. 1st, to continue to keep with the theme of transparency to ensure Continued transparency, that is very important to us. And that's why we chose to voluntarily disclose a subpoena we received from the SEC last month.
I think secondly, as I discussed today, the scope of the subpoenas related to our channel inventory and sales practices prior to the middle of last year after we reduced channel inventory and changed our distribution strategy. And you can appreciate this that I'm not able to provide more detail Since we don't comment on litigation or regulatory investigations, but I can say we're cooperating with the SEC and we believe our actions were appropriate. We remain confident And our business strategy and also the decision to make a change in our distribution channel strategy. And our teams will continue to be highly focused on executing Umer against our outlook in 2021 and driving long term Shareholder value, which I think we demonstrated with consistent business performance at or above expectations over the past year. And As much as I appreciate the desire for more details that comes with this transparency at this current time, we do not intend to provide further comment Except when in compliance with security laws.
We'll take the next caller.
Your next question is from Nathan Rich with Goldman Sachs.
Hi, good morning. Thanks for the questions. Just 2 on the revenue outlook for the back half of the year. The change in the expectations for ZovaShield led to a pretty large In the guidance for new products that $15,000,000 reduction that you called out, especially with pet health running ahead of your Expectations with the new launches there. So could you just maybe talk about your updated assumptions for ZovaShield and maybe how we should think about Additional variability in the back half of the year.
And then if I could also just ask on the competition in parasiticides, Jeff, that you Called out with some of the changing dynamics you've seen. Are you still expecting that $50,000,000 revenue headwind from competition this year? Thank you.
Nathan, let me just anchor back on some important points. First on ZoaShield, it's an externally sourced product To build out our Raised Without Antibiotic portfolio, as Todd highlighted, we believe strongly that this portfolio is well positioned to be competitive And the medium and long term, so this is an alternative coccidiostat, and and fits nicely as a portfolio play. It's Currently, I mean, let me speak very directly on what has happened. It's currently facing greater than anticipated market supply Of a leading competitive product or said another way, there's currently more supply from this competitive product than we anticipated As we go into these health program rotations with poultry integrators. So this dynamic is Discrete, maybe a little bit more short term in nature, it's leading to a reduced innovation outlook for this product.
We remain confident And our overall value contributions we see from ZoaShield and our poultry portfolio and more so I want to reiterate And no change to our 2025 innovation revenue target, that $600,000,000 to $700,000,000 range that we updated in June with the KindredBio And more to come. And I would pivot too to the 2 critical platforms of new products In that portfolio of 8 that matter the most are Credelio platform, again, Credelio Plus, Credelio Cat, exceeding Expectations and Experior tracking very nicely on that track to be a blockbuster that we've talked about. Relative, Nathan, to the parasiticide competition, It's playing out as expected, and as we've even talked about it. New innovation is impacting some of the older brands across the industry, Ours and others innovation is driving and expanding the parasiticide market. It is growing Nicely as an overall segment.
So the impact has come to our Trifexis a little bit more. But when I Back, Nathan, and I look at the pushes and pulls of our global parasiticide strategy, the proof points are pretty evident The things are tracking and we're in a very strong position. We see the Credelio franchise here in the U. S. And globally growing, Driven by vet clinic traffic and a good industry backdrop as well as growth in EDI sales, Credelio Plus, Credelio Cat, As I mentioned, new products, retail continuing to do well.
And then when I broaden it out even a little further, we're seeing nice growth in international markets. Anage is doing well in Asia, as we've mentioned, again exceeding expectations and Seresto is on track to meet our 2021 expectations. So Pushes and pulls, pipeline progressing, we're in a good place overall in global parasiticides.
We'll move to the next caller, please.
Your next question is from Chris Schott with JPMorgan.
Great. Thanks so much for the questions. I just had 2 here. I think you mentioned in the opening remarks that there was some moderation in pet health trends reflected in the second half guidance. I was hoping you could elaborate a little bit on, is that something that you're seeing already there or expecting?
I'm just trying to get a sense of what's kind of leading to that expectation? And then second question was on, I think you mentioned weather impacting the OTC business in May. Can you just help us quantify a little bit of what you saw there? I'm just trying to we think about the 2Q results overall,
how much of an impact that is? We're trying to think about more
of a normalized result on the quarter. Thanks so much.
Yes, Chris, I would say overall, I want to highlight a few things in these trends. I think that it's a little early To say what's going to stick post the pandemic. But as we highlighted, and I think other companies have highlighted, the trends are significant that Numbers of pets have gone up globally. Pet visits have gone up globally, U. S.
And international. We do believe, I mean, our The headline here is we do believe that the 2020 growth that came from COVID will lessen, But the direction of the trends and the market changes will not reverse. They will stick. We've seen a rising of the overall level of the marketplace, which is positive. We though when we look at what's really driving the ultimate growth, vet clinic traffic, we believe, will start to go more to that 2 year average versus where we are today as we move through the second half.
So moving from double digit growth And those vet clinic traffic to seeing it move to maybe more low single digit. That is what we're predicting and assuming. We're seeing That from the standpoint of, just the ability to sustain this, we think, is a challenge. I think retail purchasing as well has had, as you know, a Significant growth, especially e commerce, fastest growing segment. We see that lessening a little bit as well.
Joe, There's 2 things happen. 1, activity goes back up in the household. And 2 is innovation in the vet market It has also driven, I think, some move to the vet market. I think Elanco is well positioned with omnichannel portfolio and geo expansion. Relative to your second question, yes, we saw a cooler May.
We saw a rebound in June. I don't know if we're going to quantify that At this time, but again, what we believe is that the message we would say is, relative to the tough compares, Advantage and Seresto So we're tracking to our overall expectations for the year.
We'll take the next question.
Your next question is from Jon Block with Stifel Financial.
Great. Thanks and good morning guys. Todd, maybe for the first one for the innovation bucket. It It seems like the $15,000,000 ZovaShield, it appears as maybe more of a push than loss. So when we think about the ramp of the innovation bucket in the next year, Is it fair to say that the year 2 contribution is greater than the year 1 just when we try to isolate The innovation bucket revenue contribution to growth going forward.
And then Jeff, to circle back
on Seresto My figures, I think SIROS was up 35% from 1Q 2021 to 1Q 2019, some of the color you gave last quarter. And then it looks like 2Q was up 5%. I know you said it got better in June, but maybe if you can just talk about that disparity, why you have the confidence that Still on track for your 2021 expectations? And just more broadly speaking, why you think it's more weather related than market share? Thanks, guys.
Sure, John.
Thanks for
the question. We're not getting into 2022 guidance. But as we've noted previously, The innovation portfolio, we have expected it to be growing faster in the second half from a contribution in 2021 to That what it would do in the first half of twenty twenty one, you can then assume that that ramp would continue in the course of 2022 As you know, Experior is something we'll continue to lay the groundwork on getting the packer integration and the like, but then once that becomes Standard feeding protocol in the feed yards, that becomes just standard course that continues to grow. So I think it is a reasonable assumption to assume That back half contribution would have been a better ramp into 2022.
John, great question on Seresto. Let me just highlight, I think at the highest level, you're exactly right on the trends. I'll reiterate that we're tracking overall with the expectations we have. We did know that the ramp that came from COVID was unusual and higher than normal. Here's the things we're looking at.
First of all, the Probably no work no more work has been done in a 4 or 5 month period than last 4 or 5 months on Seresto. And what we would tell you is, 1, we stand behind the safety of the product. 2, proprietary research that we've done shows the belief in the product from pet owners And veterinarians, we've increased the advocacy by the veterinarian as well to this product. It's serving a niche and a need when you look at duration And cost and economics, that's important. We've increased our capabilities on digital.
And then I think most importantly is the global Kind of focus, especially in international with our increased dedicated investments and capabilities like digital and omnichannel. So with these, As we look at overall good strong IP protection, stronger capabilities as an independent Elanco maybe versus Bayer, again, we see this as a Product with a long runway of value that can help drive overall growth as a key focus brand for our company.
Next Caller, please.
Our next question is from Steve Scala with Cowen.
You mentioned the higher tax rate is due in part to higher corporate tax rates in the UK, But doesn't the UK tax rate increase from 19% to 25% as of April of 2023? If yes, Then why is the impact occurring now? And the second question is one of just curiosity. If If Elanco delivers full year earnings at the midpoint of the range, then 65% of earnings would be delivered in the first half. In 2018 2019, about 50% of earnings were delivered in the first half, also true of 2020 That that was an unusual year.
You noted a handful of temporary factors, but I'm wondering if there's any permanent factors that will drive this trend into the future. Thank you.
Sure, Steve. Thanks for the question. The remeasurement of the U. K. Is really driven by the deferred tax Into effect at one time when the tax law rate change is enacted.
And so that's the reason it's happening now versus Later as on those longer term assets. Then with respect to the EPS bid, yes, this is the fundamental change that has happened with the Bayer Acquisition with Seresto historically has been about 70% of its sales is in the first half of the year, 8 families close to 60% in the first half of the year. So that dugs into about a $250,000,000 In the first half of the year versus the second half of the year from those two products and with that you get a substantially larger EPS impact Just from the timing of those revenue numbers, we expect that will persist. Clearly, as we get growth in different aspects of our business over time, That can affect the mix, but here in 'twenty one, that was expected. That's why when we've given guidance both for Q1 and Q2, we've called it out.
Always a little bit of timing and shifts between quarters. So if we look at a first half aspect of $0.65 of EPS, That's about the right percentage, as you know, for the dollar at the midpoint for the full year. And then as we go into 2022, we'd expect a similar seasonality to occur. As I mentioned, we called out some phasing of Expenses or Aqua sales, those things are always going to happen in a broad based global business like we have, but the seasonality will certainly continue And in line with how we've been guiding since December of last year.
And then I think the normalization, Steve, as you look at a Kindred portfolio coming on, we move to Non parasiticide growth in pet health as well as in Exterior and our farm animal business, cattle and poultry, we see this over time with innovation normalizing. But at
Your next question is from Balaji Prasanth of Barclays.
Hi, good morning. So two part questions for me. Firstly on ASF, I just want to call out some recent developments, especially the Outbreak of ASF in the Dominican Republic and inquire whether this could pose a risk to a swine survival for the industry and you Maybe some specific commentary around the possibilities around ASF entering the U. S. From this region.
And secondly, you called out Reemerging ASF pressure with falling hog prices. I'm not sure I got the full connection there. Could you comment on that and your expectations around these trends? Thanks.
Yes. Great question, Blasey. So just at a high level, as we noted in our comments, African swine fever Did have an impact as we've talked about in the first half just overall to the Chinese industry pig industry slaughter rates were Unexpectedly high in Q2 and that pushed pork production up, the sudden supply increase impacted some Supply demand and we saw again about a decline of about 65% since the start of the year as I mentioned. We're going to monitor this going forward. Our overall business continues to be very strong in China, but this Surge we saw in the Q1 will lessen as we go into the second half.
If I look at African swine fever, specifically even in the Dominican, I believe that in the risk of that, I believe all the right measures are being taken in place by the U. S. And Mexican Industries, Biosecurity is at a different place than it was in China when the virus hits China. And I'm confident that at this point in It doesn't have any impact on our material impact on our business in Latin America. And I do believe that the industry has the right things in place as we go forward.
Thanks.
Thanks. We'll move to the next question.
Your next question is from Elliot Wilbur with Raymond James.
Thanks. Good morning. Just wanted to ask a question around synergy target progression and cash cost spending Against that, I presume your 2021 synergy targets are in fact intact, but specifically wanted to focus more on the cash costs associated with Realizing those synergies, I think it was previously $160,000,000 just in light of some of the inflationary pressures that we're seeing sort of Across markets. And then follow-up question for Todd. Can you just talk a little bit about operating cash flow in the quarter?
Just what that number was and I know it's still sort of early days in the integration here. There's lots of moving parts On the working capital side, but if there's anything that you could give us at this point to sort of help us think about Conversion operating cash flow conversion relative to adjusted net or adjusted EBITDA, just Any help there in sort of trying to model operating cash flow going forward? Thanks.
Sure, Elliot. Thanks for the question. Synergy tracking is going very well. The team has delivered on the productivity initiatives. Our manufacturing team continues to Over deliver in this area of finding opportunities to reduce the number of heads needed to drive our manufacturing facilities And continuing to capture that.
A large part of the cash cost to capture those synergies related to the layoffs That we did with the restructuring announcements from September of last year and then in January, from an inflationary pressure that has less of an impact. And then we're also doing a lot of combination of purchasing, especially with media spend and other agency related costs. We are Fighting against some inflationary pressure there, but we have better buying power now as a combined company with Bayer. So overall, feel good about how that is tracking. As we look at the cost to both integrate BEAR as well as to set up our separate ERP system, You're pleased that we went from an $80,000,000 of cash spend in Q1 to only $20,000,000 in Q2.
And that's with us going live on the ERP system in Q1. Most of the integration from Bayer being completed, that is getting lower. Now a lot of work to be done, a lot of great work by our global team to use the new system, transition to new processes and the like. We are continuing to stabilize the system and then we'll be looking towards, all right, how do we integrate the TCS system that we had with The BEARs business is being run on versus our SAP 4HANA system where we're operating Our business on to integrate those in to drive additional savings in the back half of the 2025 timeframe we've talked about. So all those things in play.
With respect to operating cash flow, we will be filing the 10 Q shortly. As a reminder, in Q1, we had $22,000,000 of operating cash flow. In Q2, operating cash flow jumped to $149,000,000 And again, that's continued execution on these items of the integration popping up and then just continued cash conversion On our working capital goals and the like. So overall, tracking very well on all those items as we move through 2021.
We'll take our last question.
Your last question is from Nivon Thai with Citi.
Hi, good morning. Can you comment on the higher cost? I think you mentioned higher transportation costs. Is that Company specific or otherwise. And then a follow-up on ZoraShield.
Are you able to comment on the supply and also the demand dynamic? And what did you expect and what has differed from your expectations? Thank you.
Yes. Navin, thanks for the question. I think overall, the logistics costs and just the global freight and the mechanisms to get product moved Across the world continues to be more disrupted by the COVID and the bounce backs and labor issues that I think we expected. And then We're seeing some inflation playing in there as well. Teams opening up different trade routes.
We're dealing with this in a very proactive manner, but We are seeing those costs come through and wanted to highlight it. From a pricing standpoint, we continue to think we will get a 2% Price improvement across our portfolio in 2021 and we look for opportunities engrossed in that or other ways to continue to be sure we're not missing out of opportunities on that end from our own level. With respect to the question on ZoaShield, as we've mentioned, this was a dynamic of Supply in the market already as poultry producers in the non antibiotic space look at how they want to operate. This is something that we are focused on. Again, overall, dollars 15,000,000 on our 4 point Yes, dollars 6,800,000,000 to $4,730,000,000 revenue is a small percentage.
We're looking across and very pleased that our other innovation is tracking Ahead of expectations and we'll continue to do that as we look at the business going forward. So That's where we land at the moment, and we'll continue to update over the course of 2021.
I'll close by, As we close out the first half, thanking all of you for your interest and the questions today and look forward to working and engaging with you in the second half. Again, good strong fundamentals in the marketplace. The strategy is working. Execution is extremely strong in Elanco. Good momentum is highlighted and exceeding our expectations and raising guidance for the 3rd time And look forward again in engaging with you as we go forward.
Thank you for your time today.
Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.